Volume 24, Issue 6 (sep 2016)                   JSSU 2016, 24(6): 491-500 | Back to browse issues page

XML Persian Abstract Print


Abstract:   (5940 Views)

Introduction: Cisplatin is a widely used anti-cancer drug, which its application is limited by nephrotoxicity. In this study, the effect of pretreatment with different l-arginine doses on Cisplatin-induced renal functional injury was investigated.

Methods: 63 male rats were divided into 7 groups: In groups 3, 4, 5 and 6, 60 min before the Cisplatin injection (5mg/kg); L-Arginine with doses of 50,100,200 or 400mg/kg was injected, respectively. In group7, normal saline was injected before Cisplatin administration. In groups 1 and 2, normal saline was injected instead of Cisplatin. In group 2, 60min before normal saline injection, 400mg/kg L-Arginine was administered and in group1, instead of L-arginine, normal saline was injected too. Injections were intraperitoneal. 72h after Cisplatin injection, blood sampling and plasma separation were done. Urine sample was collected 24 hours before blood sampling by metabolic cage. The mean of plasma urea and creatinine levels and creatinine clearance (ml/day.kg) and fractional excretion of Na (FENa, %) were compared among different groups as renal functional parameters.

Results: In comparison to group 7, L-arginine injection in a dose of 400mg/kg led to significant amelioration of all parameters. 200 mg/kg L-arginine administration led to significant decrease in plasma urea level and FENa. 100mg/kg L-arginine caused significant improvement in fractional excretion of sodium. L-arginine injection with 50mg/kg dose, significantly ameliorate all renal function tests instead of creatinine clearance.

Conclusion: Pretreatment with L-arginine administration with 400 or 50 mg/kg doses, respectively, had the highest effect on reducing Cisplatin-induced nephropathy. L-arginine injection with intermediate doses i.e. 200 or 100 mg/kg had less effect in reducing Cisplatin-induced nephropathy and it needs more investigations.

Full-Text [PDF 419 kb]   (1522 Downloads)    
Type of Study: Original article | Subject: Physiology
Received: 2015/05/22 | Accepted: 2016/04/9 | Published: 2016/10/4

References
1. 1- Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006; 44(8): 1173-83.
2. 2- Saleh S, El-Demerdash E. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 2005; 97(2): 91-7.
3. 3- Oh G-S, Kim H-J, Shen A, Lee SB, Khadka D, Pandit A, et al. Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies. Electrolytes Blood Pressure; 12(2): 55-65.
4. 4- Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer ChemotherPharmacol 2003; 52(1): 13-8.
5. 5- Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 2005; 148: 107-21.
6. 6- Cylwik D, Mogielnicki A, BuczkoWo. L-arginine and cardiovascular system. Pharmacol Rep 2005; 57(1): 14-22.
8. 7- Dorniak-Wall T, Grivell RM, Dekker GA, Hague W, Dodd JM. The role of L-arginine in the prevention and treatment of pre-eclampsia: a systematic review of randomisedtrials.J human hypertension 2014; 28(4): 230-5.
9. 8- Foo L, Tay J, Lees C, McEniery C, Wilkinson I. Hypertension in Pregnancy: Natural History and Treatment Options. Current hypertension reports 2015; 17(5): 1-18.
10. 9- Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Lib 2007; 1: CD002252
11. 10- Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012; 18(8): 2344-51.
12. 11- McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New En J Med 1996; 334(1): 1-6.
13. 12- Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydøy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clinic Oncol 2012; 30(30): 3752-63.
14. 13- Beiranvand A, Rasoulian B, Alirezaei M, Hashemi P, Pilevarian A, Ezatpour B. Pretreatment with Olive Leaf Extract partially attenuates cisplatin induced nephrotoxicity in rats. Yafte 2010; 11(5): 35-44. [Persian]
15. 14- Eliopoulos N, Zhao J, Bouchentouf M, Forner K, Birman E, Yuan S, et al. Human marrow-derived mesenchymal stromal cells decrease cisplatinrenotoxicity in vitro and in vivo and enhance survival of mice post-intraperitonealinjection. Am J Physiology-Renal Physiol 2010; 299(6): F1288-F98.
16. 15- Schramm L, La M, Heidbreder E, Hecker M, Beckman JS, Lopau K, et al. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney Int 2002; 61(4): 1423-32.
17. 16- Saad SY, Najjar T, Daba MH, Al-Rikabi AC. Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine. Chemotherapy 2001; 48(6): 309-15.
18. 17- Li Q, Bowmer C, Yates M. The Protective Effect of Glycine in Cisplatin Nephrotoxicity: Inhibition with NG‐Nitro‐l‐arginine Methyl Ester. J pharmacy pharmacol 1994; 46(5): 346-51.
19. 18- Quan L, Bowmer CJ, Yates MS. Effect of arginine on cisplatin-induced acute renal failure in the rat. Biochempharmacol 1994; 47(12): 2298-301.
20. 19- Chander V, Chopra K. Renal protective effect of molsidomine and L-arginine in ischemia-reperfusion induced injury in rats. J Surgic Res 2005; 128(1): 132-39.
21. 20- Mansour M, Daba MH, Gado A, Al-Rikabi A, Al-Majed A. Protective effect of L-arginine against nephrotoxicity induced by cyclosporine in normal rats. Pharmacological Res 2002; 45(6): 441-6.
22. 21- Can C, Şen S, Boztok N, TuǧlularIk. Protective effect of oral L-arginine administration on gentamicin-induced renal failure in rats. Euro J Pharmacol 2000; 390(3): 327-34.
23. 22- Ito K, Chen J, Vaughan ED, Seshan SV, Poppas DP, Felsen D. Dietary L-arginine supplementation improves the glomerular filtration rate and renal blood flow after 24 hours of unilateral ureteral obstruction in rats. J Urology 2004; 171(2): 926-30.
24. 23- Rasoulian B. Pretreatment with L-Arginine Protects Rat Renal Tubules from Ischemia-Reperfusion Injury. 8th Ann Congress Iranian Society Pathology; Tehran, Iran2006. p. 236.
25. 24- De Cobelli F, Fiorina P, Perseghin G, Magnone M, Venturini M, Zerbini G, et al. L-arginine-induced vasodilation of the renal vasculature is preserved in uremic type 1 diabetic patients after kidney and pancreas but not after kidney-alone transplantation. Diabetes Care2004; 27(4): 947-54.

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.